ArticleFood science & nutrition2026
Alliin Regulates Intracellular Cholesterol Metabolism Through the PCSK9/LDLR Axis in Ox-LDL-Induced HepG2 Cells: A Proteomics Study.
Article in Food science & nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study focuses on alliin, a bioactive compound derived from garlic, and investigates its underlying mechanisms through a proteomics-based approach. In HepG2 cells, alliin significantly reduced intracellular total cholesterol and triglyceride levels. Tandem mass tag-based quantitative proteomic analysis identified 67 differentially expressed proteins (53 upregulated, 14 downregulated). Bioinformatics enrichment revealed these proteins were primarily involved in cholesterol metabolism, the PPAR signaling pathway, and the PI3K/Akt pathway. Notably, alliin significantly upregulated low-density lipoprotein receptor (LDLR) expression while downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9). Western blot validation confirmed that alliin modulates the PCSK9/LDLR pathway. In conclusion, alliin influences intracellular cholesterol metabolism in HepG2 cells, potentially through regulation of the PCSK9/LDLR pathway. These findings provide mechanistic insights at the cellular level and suggest that alliin may serve as a candidate compound for further investigation in the context of lipid metabolism-related disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.